c-MET-targeted antibody-drug conjugate

DRUG CLASS:

c-MET-targeted antibody-drug conjugate

News alerts, weekly reports and conference planners

Related drugs:

EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: B - Late Trials ABBV-399 Sensitive : B	ABBV-399 Sensitive: B - Late Trials ABBV-399 Sensitive : B
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria erlotinib + ABBV-399 Sensitive : C2	erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria erlotinib + ABBV-399 Sensitive : C2
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET expression	Solid Tumor	MET expression	Solid Tumor	BYON3521 Sensitive: C2 – Inclusion Criteria BYON3521 Sensitive : C2	BYON3521 Sensitive: C2 – Inclusion Criteria BYON3521 Sensitive : C2
MET amplification	Solid Tumor	MET amplification	Solid Tumor	ABBV-400 Sensitive: C2 – Inclusion Criteria ABBV-400 Sensitive : C2	ABBV-400 Sensitive: C2 – Inclusion Criteria ABBV-400 Sensitive : C2
MET positive	Lung Non-Squamous Non-Small Cell Cancer	MET positive	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive	Lung Non-Small Cell Squamous Cancer	MET positive	Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
EGFR mutation	Lung Non-Small Cell Squamous Cancer	EGFR mutation	Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET overexpression + EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression + EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: C3 – Early Trials ABBV-399 Sensitive : C3	ABBV-399 Sensitive: C3 – Early Trials ABBV-399 Sensitive : C3
MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3
MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	BYON3521 Sensitive: C3 – Early Trials BYON3521 Sensitive : C3	BYON3521 Sensitive: C3 – Early Trials BYON3521 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3
TMB-H	Colorectal Cancer	TMB-H	Colorectal Cancer	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3	ABBV-400 Sensitive: C3 – Early Trials ABBV-400 Sensitive : C3
EGFR mutation + MET overexpression	Non Small Cell Lung Cancer	EGFR mutation + MET overexpression	Non Small Cell Lung Cancer	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AZD9592 Sensitive: D – Preclinical AZD9592 Sensitive : D	AZD9592 Sensitive: D – Preclinical AZD9592 Sensitive : D
EGFR expression + MET expression	Pancreatic Ductal Adenocarcinoma	EGFR expression + MET expression	Pancreatic Ductal Adenocarcinoma	DM005 Sensitive: D – Preclinical DM005 Sensitive : D	DM005 Sensitive: D – Preclinical DM005 Sensitive : D
EGFR expression + MET expression	Non Small Cell Lung Cancer	EGFR expression + MET expression	Non Small Cell Lung Cancer	DM005 Sensitive: D – Preclinical DM005 Sensitive : D	DM005 Sensitive: D – Preclinical DM005 Sensitive : D
TPBG expression + MET expression	Lung Cancer	TPBG expression + MET expression	Lung Cancer	DM004 Sensitive: D – Preclinical DM004 Sensitive : D	DM004 Sensitive: D – Preclinical DM004 Sensitive : D
TPBG expression + MET expression	Gastric Cancer	TPBG expression + MET expression	Gastric Cancer	DM004 Sensitive: D – Preclinical DM004 Sensitive : D	DM004 Sensitive: D – Preclinical DM004 Sensitive : D
MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
MET expression	Solid Tumor	MET expression	Solid Tumor	MYTX-011 Sensitive: D – Preclinical MYTX-011 Sensitive : D	MYTX-011 Sensitive: D – Preclinical MYTX-011 Sensitive : D
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	osimertinib + AZD9592 Sensitive: D – Preclinical osimertinib + AZD9592 Sensitive : D	osimertinib + AZD9592 Sensitive: D – Preclinical osimertinib + AZD9592 Sensitive : D
MET expression	Non Small Cell Lung Cancer	MET expression	Non Small Cell Lung Cancer	REGN5093-M114 Sensitive: D – Preclinical REGN5093-M114 Sensitive : D	REGN5093-M114 Sensitive: D – Preclinical REGN5093-M114 Sensitive : D
MET underexpression	Solid Tumor	MET underexpression	Solid Tumor	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D	TR1801-ADC Sensitive: D – Preclinical TR1801-ADC Sensitive : D
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
EGFR mutation + PTEN deletion	Non Small Cell Lung Cancer	EGFR mutation + PTEN deletion	Non Small Cell Lung Cancer	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D
MET Y1230C	Non Small Cell Lung Cancer	MET Y1230C	Non Small Cell Lung Cancer	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D	osimertinib + savolitinib + REGN5093-M114 Sensitive: D – Preclinical osimertinib + savolitinib + REGN5093-M114 Sensitive : D

c-MET-targeted antibody-drug conjugate

c-MET-targeted antibody-drug conjugate

Associations(35)

Associations
(35)